Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 1/2019

01-02-2019 | Research Article

Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-l-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake

Authors: Carina Stegmayr, Gabriele Stoffels, Elena Rota Kops, Philipp Lohmann, Norbert Galldiks, Nadim J. Shah, Bernd Neumaier, Karl-Josef Langen

Published in: Molecular Imaging and Biology | Issue 1/2019

Login to get access

Abstract

Purpose

O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) is an established positron emission tomography (PET) tracer for brain tumor imaging. This study explores the influence of dexamethasone therapy on [18F]FET uptake in the normal brain and its influence on the maximum and mean tumor-to-brain ratio (TBR).

Procedures

[18F]FET PET scans of 160 brain tumor patients were evaluated (80 dexamethasone treated, 80 untreated; each group with 40 men/40 women). The standardized uptake value of [18F]FET uptake in the normal brain (SUVbrain) in the different groups was compared. Nine patients were examined repeatedly with and without dexamethasone therapy.

Results

SUVbrain of [18F]FET uptake was significantly higher in dexamethasone-treated patients than in untreated patients (SUVbrain 1.33 ± 0.1 versus 1.06 ± 0.16 in male and 1.45 ± 0.25 versus 1.31 ± 0.28 in female patients). Similar results were observed in patients with serial PET scans. Furthermore, compared to men, a significantly higher SUVbrain was found in women, both with and without dexamethasone treatment. There were no significant differences between the different groups for TBRmax and TBRmean, which could have been masked by the high standard deviation. In a patient with a stable brain metastasis investigated twice with and without dexamethasone, the TBRmax and the biological tumor volume (BTV) decreased considerably after dexamethasone due to an increased SUVbrain.

Conclusion

Dexamethasone treatment appears to increase the [18F]FET uptake in the normal brain. An effect on TBRmax, TBRmean, and BTV cannot be excluded which should be considered especially for treatment monitoring and the estimation of BTV using [18F]FET PET.
Appendix
Available only for authorised users
Literature
1.
Langen KJ, Watts C (2016) Neuro-oncology: amino acid PET for brain tumours—ready for the clinic? Nat Rev Neurol 12:375–376CrossRefPubMed
2.
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18:1199–1208CrossRefPubMedPubMedCentral
3.
Galldiks N, Langen K, Holy R et al (2012) Assessment of treatment response in patients with glioblastoma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. J Nucl Med 53:1048–1057CrossRefPubMed
4.
Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, Tellmann L, Jansen P, Reifenberger G, Hamacher K, Coenen HH, Langen KJ (2009) Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nucl Med Biol 36:779–787CrossRefPubMed
5.
Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nußbaumer K, Topakian R, Aigner RM (2010) Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 37:1521–1528CrossRefPubMed
6.
Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464–1470CrossRefPubMed
7.
Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, Jansen P, Coenen HH, Steiger HJ, Langen KJ (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519–527CrossRefPubMed
8.
Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn JC, Bartenstein P, Kreth FW, la Fougere C (2015) Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med 56:9–15CrossRefPubMed
9.
Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, Kurlemann G, Wassmann H, Coenen HH, Schober O (2005) O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 32:422–429CrossRefPubMed
10.
Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, Baum RP (2011) Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 36:841–847CrossRefPubMed
11.
Galldiks N, Langen KJ (2015) Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q J Nucl Med Mol Imaging 59:70–82PubMed
12.
13.
Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294CrossRefPubMed
14.
Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G (1999) Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40:205–212PubMed
15.
Kotsarini C, Griffiths PD, Wilkinson ID, Hoggard N (2010) A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors. Neurosurgery 67:1799–1815 discussion 1815CrossRefPubMed
16.
Sarin R, Murthy V (2003) Medical decompressive therapy for primary and metastatic intracranial tumours. Lancet Neurol 2:357–365CrossRefPubMed
17.
Stegmayr C, Bandelow U, Oliveira D, Lohmann P, Willuweit A, Filss C, Galldiks N, Lübke JHR, Shah NJ, Ermert J, Langen KJ (2017) Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas. Eur J Nucl Med Mol Imaging 44:408–416CrossRefPubMed
18.
Stegmayr C, Oliveira D, Niemietz N, Willuweit A, Lohmann P, Galldiks N, Shah NJ, Ermert J, Langen KJ (2017) Influence of bevacizumab on blood-brain barrier permeability and O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas. J Nucl Med 58:700–705CrossRefPubMed
19.
Stegmayr C, Schoneck M, Oliveira D et al (2016) Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. Eur J Nucl Med Mol Imaging 43:1115–1123CrossRefPubMed
20.
Hamacher K, Coenen HH (2002) Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot 57:853–856CrossRefPubMed
21.
Langen KJ, Bartenstein P, Boecker H et al (2011) German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin 50:167–173CrossRefPubMed
22.
Herzog H, Langen KJ, Weirich C et al (2011) High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin Nucl Med 50:74–82CrossRef
23.
Rota Kops E, Hautzel H, Herzog H, Antoch G, Shah NJ (2015) Comparison of template-based versus CT-based attenuation correction for hybrid MR/PET scanners. IEEE Trans Nucl Sci 62:2115–2121CrossRef
24.
Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ (2013) Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 54:229–235CrossRefPubMed
25.
Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:1316–1322CrossRefPubMed
26.
Beaufrere B, Horber FF, Schwenk WF et al (1989) Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Phys 257:E712–E721
27.
Garrel DR, Moussali R, De Oliveira A et al (1995) RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism. J Clin Endocrinol Metab 80:379–385PubMed
28.
Schwertfeger M, Pissowotzki K, Fleck C, Taylor PM (2003) Regulation of L-leucine transport in rat kidney by dexamethasone and triiodothyronine. Amino Acids 25:75–83CrossRefPubMed
29.
Varlamov O, Bethea CL, Roberts CT Jr (2014) Sex-specific differences in lipid and glucose metabolism. Front Endocrinol (Lausanne) 5:241
30.
31.
Fuller CM, Insel PA (2014) I don’t know the question, but sex is definitely the answer! Focus on “in pursuit of scientific excellence: sex matters” and “do you know the sex of your cells?”. Am J Phys Cell Phys 306:C1–C2CrossRef
32.
Verger A, Stegmayr C, Galldiks N, van der Gucht A, Lohmann P, Stoffels G, Shah NJ, Fink GR, Eickhoff SB, Guedj E, Langen KJ (2018) Evaluation of factors influencing 18F-FET uptake in the brain. Neuroimage Clin 17:491–497CrossRefPubMed
33.
Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Müller HW, Coenen HH, Langen KJ (2003) Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging 30:519–524CrossRefPubMed
Metadata
Title
Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-l-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake
Authors
Carina Stegmayr
Gabriele Stoffels
Elena Rota Kops
Philipp Lohmann
Norbert Galldiks
Nadim J. Shah
Bernd Neumaier
Karl-Josef Langen
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 1/2019
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-018-1221-z

Other articles of this Issue 1/2019

Molecular Imaging and Biology 1/2019 Go to the issue

Research Article

The Value of In Vitro Binding as Predictor of In Vivo Results: A Case for [18F]FDDNP PET

Research Article

Bioluminescence Imaging of Transplanted Mesenchymal Stem Cells by Overexpression of Hepatocyte Nuclear Factor4α: Tracking Biodistribution and Survival

Research Article

Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

Research Article

Zero-Extra-Dose PET Delayed Imaging with Data-Driven Attenuation Correction Estimation

Research Article

An Innovation for Treating Orthotopic Pancreatic Cancer by Preoperative Screening and Imaging-Guided Surgery

Research Article

Ultrahigh-Field Quantitative MR Microscopy of the Chicken Eye In Vivo Throughout the In Ovo Period